|
1
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sharma C, Eltawil KM, Renfrew PD, Walsh MJ
and Molinari M: Advances in diagnosis, treatment and palliation of
pancreatic carcinoma: 1990–2010. World J Gastroenterol. 17:867–897.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones MH, Furlong RA, Burkin H, Chalmers
J, Brown GM, Khwaja O and Affara NA: The Drosophila developmental
gene fat facets has a human homologue in Xp11.4 which escapes
X-inactivation and has related sequences on Yq11.2. Hum Mol Genet.
5:1695–1701. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dasgupta S, Jang JS, Shao C, Mukhopadhyay
ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, et al:
SH3GL2 is frequently deleted in non-small cell lung cancer and
downregulates tumor growth by modulating EGFR signaling. J Mol Med
(Berl). 91:381–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing
T, Dong L, Tang E and Yang H: Over-expression of genes and proteins
of ubiquitin specific peptidases (USPs) and proteasome subunits
(PSs) in breast cancer tissue observed by the methods of RFDD-PCR
and proteomics. Breast Cancer Res Treat. 104:21–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie Y, Avello M, Schirle M, McWhinnie E,
Feng Y, Bric-Furlong E, Wilson C, Nathans R, Zhang J, Kirschner MW,
et al: Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin
ligase SMURF1 protein and protects it from ligase
activity-dependent self-degradation. J Biol Chem. 288:2976–2985.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng J, Hu Q, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Wei W, Liu S and Wang H: USP9X expression correlates
with tumor progression and poor prognosis in esophageal squamous
cell carcinoma. Diagn Pathol. 8:1772013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peddaboina C, Jupiter D, Fletcher S, Yap
JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR and
Cao X: The downregulation of Mcl-1 via USP9X inhibition sensitizes
solid tumors to Bcl-xl inhibition. Bmc Cancer. 12:5412012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harris DR, Mims A and Bunz F: Genetic
disruption of USP9X sensitizes colorectal cancer cells to
5-fluorouracil. Cancer Biol Ther. 13:1319–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Kollipara RK, Srivastava N, Li R,
Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P,
Lotan Y, et al: Ablation of the oncogenic transcription factor ERG
by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci
USA. 111:4251–4256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rolen U, Kobzeva V, Gasparjan N, Ovaa H,
Winberg G, Kisseljov F and Masucci MG: Activity profiling of
deubiquitinating enzymes in cervical carcinoma biopsies and cell
lines. Mol Carcinog. 45:260–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun H, Kapuria V, Peterson LF, Fang D,
Bornmann WG, Bartholomeusz G, Talpaz M and Donato NJ: Bcr-Abl
ubiquitination and Usp9x inhibition block kinase signaling and
promote CML cell apoptosis. Blood. 117:3151–3162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwickart M, Huang X, Lill JR, Liu J,
Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F,
Eastham-Anderson J, et al: Deubiquitinase USP9X stabilizes MCL1 and
promotes tumour cell survival. Nature. 463:103–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pérez-Mancera PA, Rust AG, van der Weyden
L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R,
Aust D, Rümmele P, et al: The deubiquitinase USP9X suppresses
pancreatic ductal adenocarcinoma. Nature. 486:266–270.
2012.PubMed/NCBI
|
|
16
|
Cox JL, Wilder PJ, Wuebben EL, Ouellette
MM, Hollingsworth MA and Rizzino A: Context-dependent function of
the deubiquitinating enzyme USP9X in pancreatic ductal
adenocarcinoma. Cancer Biol Ther. 15:1042–1052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang H, Li Q, He C, Li F, Sheng H, Shen
X, Zhang X, Zhu S, Chen H, Chen X, et al: Activation of the Wnt
pathway through Wnt2 promotes metastasis in pancreatic cancer. Am J
Cancer Res. 4:537–544. 2014.PubMed/NCBI
|
|
19
|
Yang JY, Jiang SH, Liu DJ, Yang XM, Huo
YM, Li J, Hua R, Zhang ZG and Sun YW: Decreased LKB1 predicts poor
prognosis in Pancreatic Ductal Adenocarcinoma. Sci Rep.
5:158692015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huo Y, Yang M, Liu W, Yang J, Fu X, Liu D,
Li J, Zhang J, Hua R and Sun Y: High expression of DDR1 is
associated with the poor prognosis in Chinese patients with
pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 34:882015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saka B, Balci S, Basturk O, Bagci P,
Postlewait LM, Maithel S, Knight J, El-Rayes B, Kooby D, Sarmiento
J, et al: Pancreatic ductal adenocarcinoma is spread to the
peripancreatic soft tissue in the majority of resected cases,
rendering the AJCC T-stage protocol (7th Edition) inapplicable and
insignificant: A size-based staging system (pT1: ≤na pT2: & gt;
2- & c pT3: & gt; 4 cm) is more valid and clinically
relevant. Ann Surg Oncol. 23:2010–2018. 2016. View Article : Google Scholar : PubMed/NCBI
|
